Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be linked to liver, heart and gastrointestinal problems

The Independent UK

Wegovy maker announces partnership with OpenAI

IN FULL

The Independent UK

Wegovy maker and OpenAI partnering to speed up search for new drugs

The Danish drug manufacturer announced the partnership Tuesday, noting that the goal was to bring ‘new and better treatment options to patients faster’

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk joins forces with OpenAI to fast-track drug research

Danish pharma company Novo Nordisk has announced a partnership with OpenAI to apply artificial intelligence across its drug development process.

Euronews

Trump sets 100% tariffs on prescription drugs from companies that have not reached a deal with him to lower prices

The tariffs were announced on the anniversary of Trump’s ‘Liberation Day,’ which saw U.S. trading partners hit with sweeping levies

The Independent UK

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Barchart

Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable

IN FULL

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs

A bipartisan group of senators is aiming to relieve high insulin costs for more Americans

The Independent UK

US approves new oral weight-loss pill developed by Eli Lilly

Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy

The Guardian - US

Foundayo: All you need to know about the newly approved weight-loss pill

The FDA authorized Eli Lilly's drug as part of a new program aimed at cutting drug approval times

The Independent UK

NHS to roll out weight-loss jabs for patients at risk of repeat heart attacks

A weekly weight-loss injection could soon be offered on the NHS to help prevent heart attacks and strokes in high-risk patients

Evening Standard

Health warning as £10 fat jabs set to flood UK black market

As patents for the drugs near expiry, other manufacturers are already launching unlicensed versions of the skinny jabs

Evening Standard

The FDA just approved triple the previous maximum dose of Wegovy

People taking ‘Wegovy HD’ lost an average of 21 percent of their body weight after 72 weeks

The Independent UK

Stopping GLP-1s can reverse cardiovascular benefits within six months, study finds

Discontinuing the drugs leaves a ‘lasting scar,’ researchers at WashU Medicine say

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

What is ‘eye stroke’ and why has it been linked to weight loss injections?

The phrase “eye stroke” has recently appeared in news reports about a very rare side-effect of weight-loss injections. It’s not a formal medical diagnosis, but a shorthand used to describe a condition in which reduced blood flow damages the optic nerve and causes sudden vision loss.

International Business Times UK

Ozempic Controversy Deepens as FDA Accuses Novo Nordisk of Failing to Report Patient Deaths, One Linked To Suicide

Novo Nordisk faces FDA scrutiny for failing to report Ozempic-linked deaths, highlighting systemic issues in safety reporting. Learn about the implications for patient safety and ongoing legal challenges.

AAP

Label unhealthy foods, weight drug boss tells Australia

Workplace health checks, clearer labels on unhealthy foods and better education would help Australia reduce high rates of obesity, a drug company chief says.

Evening Standard

Illegal weight loss jabs being sold in London pubs and fish and chip shops, report claims

It is alleged beauticians and personal trainers are exploiting soaring interest in weight loss jabs

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Feds warn Ozempic and Wegovy maker over failure to report side-effects from weight-loss drugs

Officials wrote that Novo Nordisk had failed to failed to report ‘serious and unexpected’ adverse drug experiences

The Independent UK

Weight loss jab ‘may carry higher risk of sudden sight loss’ as new warning issued

Wegovy is approved on the NHS to help people lose weight in higher doses

The Guardian - UK

Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds

‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author

MarketBeat

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

International Business Times

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

Kiplinger

Stocks Recover as Oil Retreats From $119: Stock Market Today

How high the price of crude oil rises and how long it stays there are critical questions for market participants and policymakers alike.

Barchart

Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?

Hims & Hers shares soared as Novo Nordisk dropped its GLP-1 lawsuit. But there’s reason to still sell HIMS stock today. Find out more!

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.